Latest Breaking News On - Plasma cell - Page 2 : comparemela.com

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting

Innovent and IASO Bio Updated Efficacy and Safety Clinical Data of Equecabtagene Autoleucel (BCMA CAR-T Cell Therapy) for Multiple Myeloma at the 2023 ASCO Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
Chicago
Illinois
Hong-kong
Macau
Taiwan
Mccormick-place
China
Rockville
Suzhou
Jiangsu
Huazhong

CARVYKTI® (ciltacabtagene autoleucel) Reduces Risk of Disease Progression or Death by 74 Percent in Earlier-Line Multiple Myeloma Treatment in the Landmark Phase 3 CARTITUDE-4 Study

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that results from the Phase 3 CARTITUDE-4 study showed CARVYKTI®.

United-states
Chicago
Illinois
American
Satu-glawe
Binod-dhakal
Hemophagocytic-lymphohistiocytosis
Legend-biotech-united-states-inc
National-cancer-institute
European-commission
Congress-abstract
None-of-janssen-research-development

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today long-term data from the pivotal Phase 1/2 MajesTEC-1 study showing.

Amsterdam
Noord-holland
Netherlands
Chicago
Illinois
United-states
American
Rachel-kobos
Satu-glawe
Christie-corbett
Eastern-cooperative-oncology-group
Exchange-commission

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma

Janssen Presents Longer-Term Data for TECVAYLI® (teclistamab-cqyv) Showing a Duration of Response of 22 Months in Patients with Relapsed or Refractory Multiple Myeloma
webwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from webwire.com Daily Mail and Mail on Sunday newspapers.

Amsterdam
Noord-holland
Netherlands
Chicago
Illinois
United-states
American
Rachel-kobos
American-cancer-society
Johnson
Janssen-oncology-research-development
Janssen-pharmaceutical-companies

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of.

United-states
Israel
Chicago
Illinois
American
Christie-corbett
Arnob-banerjee
Yael-cohen
Satu-glawe
Early-development-oncology
Companies-of-johnson
Janssen-pharmaceutical-companies-of-johnson